WASHINGTON, July 5, 2016 -- The Association of Academic Health Centers (AAHC) is pleased to announce the appointment of Nicholas Fisk, MBBS, PhD, MBA, deputy vice-chancellor of UNSW Australia, as chair of its international division's Steering Committee. As chair of the Association of Academic Health Centers International (AAHCI) Steering Committee, Dr. Fisk will also assume a seat on the parent AAHC board.
"This is an exciting time for our association, and we welcome Dr. Fisk with his extensive international perspective to our ongoing programs," said Dr. Steven A. Wartman, AAHC president and CEO. "As chair of the AAHCI Steering Committee, and as an AAHC board member, Dr. Fisk will bring expertise and critical perspective to our growing domestic and international programs, ensuring that they are both complementary and synergistic, while ultimately helping to increase the impact and profile of academic health centers worldwide."
A strong focus of the association is to work closely with member institutions to elaborate best practices while fostering collaboration in biomedical and clinical research, health professions education, and patient care. An integral initiative in this regard is the groundbreaking Aligned Institutional Mission (AIM) Program. The AIM Program, planned to be rolled out for application by academic health centers worldwide, focuses on optimizing the alignment among the academic health center's three key mission: education, research, and patient care/population health. "This innovative, global program is designed to assist these vital institutions in meeting the needs of their communities and nations in the challenging and exciting context of 21st century medicine," said Wartman, adding "we look forward to Dr. Fisk's experience and knowledge in assisting with the AIM Program's progress as well as with our many outreach initiatives."
Dr. Fisk joined UNSW in 2016 after serving as the executive dean of the Faculty of Medicine and Biomedical Sciences at the University of Queensland in Australia. Dr. Fisk is a leading authority in the fields of developmental biology and maternal-fetal medicine and is the author of more than 400 publications. He practices as a senior specialist at the Royal Brisbane and Women's Hospital and leads a research group on placental stem cell applications. He currently chairs the Group of Eight Deans of Medicine committee and is a visiting professor at the National University of Singapore. He is a Fellow of the Australian Academy of Health and Medical Sciences and a past Council member of the Queensland Institute of Medical Research.
AAHC is a non-profit association dedicated to advancing health and well-being through the vigorous leadership of academic health centers.
CONTACT: Angela Mills
202-265-9600
[email protected]


7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



